Skip to content

DBV Technologies DBVT Stock-Based Comp

Stock-Based Comp at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$3.58M+10.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$7.62M-18.8%
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
$8.52M-8.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$3.36M-13.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$16.01M+12.5%
Alumis Inc. logo
Alumis Inc.ALMS
$12.34M+76.4%

Segments

By product

See full
Expenses by Nature$1.7M

Other financials

Income statement

See full
Revenue$900.0K+12.5%
Operating income-$47.9M-80.1%
Net income-$47.6M-75.6%
EPS (diluted)-$0.11+57.7%

Balance sheet

See full
Cash & equivalents$229.2M+1,668%
Total debt$6.1M-15.7%
Total equity$207.9M+7,069%
Total assets$266.4M+427%

Cash flow

See full
Operating cash flow-$49.1M-149%
CapEx$400.0K
Free cash flow-$49.5M-151%

Valuation

See full
Market cap$948.17M+269%
Enterprise value$725.07M+188%
P/S163.9×+91.4×

Profitability

See full
Operating margin-2,910.4%-265pp
Net margin-2,895.4%-257pp
FCF margin-2,619.5%+69.9pp

Returns & leverage

See full
Return on equity-158.9%-26.4pp
Debt / equity-2.5×
Current ratio4.8×+4.0×

Where this comes from

Reported directly by DBV Technologies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: DBV Technologies’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about DBV Technologies's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is DBV Technologies's stock-based comp?
DBV Technologies (DBVT) reported stock-based comp of $2.3M in Q1 2026.
How has DBV Technologies's stock-based comp changed year-over-year?
DBV Technologies's stock-based comp increased by 35.3% year-over-year, from $1.7M to $2.3M.
What is the long-term trend for DBV Technologies's stock-based comp?
Over 3 years (2022 to 2025), DBV Technologies's stock-based comp has grown at a 2.3% compound annual growth rate (CAGR), from $5.03M to $5.39M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.